SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Thursday announced promising early data from its Phase 2a trial of SLS009 or tambiciclib, a highly selective CDK9 inhibitor, in combination with zanubrutinib or Brukinsa for relapsed/refractory diffuse large B-cell lymphoma or r/r DLBCL.
The trial showed an overall response rate or ORR of 67 percent more than double the expected ORR for zanubrutinib alone.
Among responders, one patient achieved a complete response or CR, while three had partial responses or PR, with target lesions shrinking by 89 percent, 78 percent, and 56 percent, respectively.
In patients with the non-GCB DLBCL or ABC subtype, the disease control rate or DCR was 83 percent.
No median overall survival or OS was reached at the time of the follow-up, but 67 percent of patients remained alive.
The safety profile was consistent with zanubrutinib alone, and no dose-limiting toxicities were observed.
SELLAS continues to explore the potential of SLS009 in DLBCL and other hematologic cancers.
Currently, SLS is trading at $1.28, up by 1.44 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.